Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Nicholas Jason Roberts

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8709-0664; OpenAlex author ID A5049406054; NIH RePORTER profile ID 12093255. Sources: OpenAlex.

Their work

Papers
30 (first author 3, last author 3)
Trials
0
Grants
2
Labs led
1
Collaborators
148
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper, 1 grant · 2017: 2 papers · 2018: 2 papers · 2019: 4 papers, 1 grant · 2020: 2 papers · 2021: 6 papers · 2022: 4 papers · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 30

  1. Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer. Co-author DOI 10.1172/jci190121↗
  2. Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cance… Co-author DOI 10.1186/s40164-025-00673-0↗
  3. Understanding familial risk of pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s10689-024-00383-2↗
  4. Screening for pancreatic cancer has the potential to save lives, but is it practical? Co-author DOI 10.1080/17474124.2023.2217354↗
  5. Intraparenchymal metastases as a cause for local recurrence of pancreatic cancer. Co-author DOI 10.1111/his.14839↗
  6. Endoplasmic stress-inducing variants in CPB1 and CPA1 and risk of pancreatic cancer: A case-control study and meta-analysis. Co-author DOI 10.1002/ijc.33883↗
  7. Endoplasmic stress-inducing variants in carboxyl ester lipase and pancreatic cancer risk. Co-author DOI 10.1016/j.pan.2022.08.004↗
  8. Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. Co-author DOI 10.1093/jnci/djac167↗
  9. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  10. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. First author DOI 10.1001/jamaoncol.2021.3701↗
  11. Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants. Co-author DOI 10.1002/gcc.22947↗
  12. Pancreatic cancer pathology viewed in the light of evolution. Co-author DOI 10.1007/s10555-020-09953-z↗
  13. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  14. Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. Last author DOI 10.1016/j.pan.2021.03.015↗
  15. The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001888↗
  16. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Co-author DOI 10.1158/0008-5472.can-19-1523↗
  17. Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. Co-author DOI 10.1158/2159-8290.cd-20-0133↗
  18. Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. Co-author DOI 10.1002/path.5194↗
  19. Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. Co-author DOI 10.1038/s41379-019-0317-6↗
  20. Biphenotypic Differentiation of Pancreatic Cancer in 3-Dimensional Culture. Co-author DOI 10.1097/mpa.0000000000001390↗
  21. A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. Co-author DOI 10.1371/journal.pgen.1008344↗
  22. Exome-Wide Association Study of Pancreatic Cancer Risk. Co-author DOI 10.1053/j.gastro.2017.10.015↗
  23. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Co-author DOI 10.1073/pnas.1720588115↗
  24. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.2017.72.3502↗
  25. Inherited pancreatic cancer. First author DOI 10.21037/cco.2017.12.04↗
  26. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-15-0402↗
  27. Familial and sporadic pancreatic cancer share the same molecular pathogenesis. First author DOI 10.1007/s10689-014-9755-y↗
  28. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Co-author DOI 10.1038/gim.2014.153↗
  29. Genome-wide sequencing to identify the cause of hereditary cancer syndromes: with examples from familial pancreatic cancer. Co-author DOI 10.1016/j.canlet.2012.11.008↗
  30. ATM mutations in patients with hereditary pancreatic cancer. Co-author DOI 10.1158/2159-8290.cd-11-0194↗

Grants 2

  1. Integrative Analyses to Identify Pancreatic Cancer Susceptibility Genes R00CA190889↗
  2. Integrative Analyses to Identify Pancreatic Cancer Susceptibility Genes K99CA190889↗

Closest collaborators

The 25 strongest of 148 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alison P. Klein · 23 shared papers, 2012–2024 · strength 2.46
  2. Ralph H. Hruban · 20 shared papers, 2012–2026 · strength 2.03
  3. Michael Goggins · 15 shared papers, 2012–2023 · strength 1.38
  4. Laura DeLong Wood · 8 shared papers, 2016–2024 · strength 0.95
  5. Jin Peng He · 10 shared papers, 2017–2022 · strength 0.92
  6. James R. Eshleman · 8 shared papers, 2012–2026 · strength 0.77
  7. Steve Gallinger · 10 shared papers, 2012–2021 · strength 0.72
  8. Daniel A. Laheru · 5 shared papers, 2021–2022 · strength 0.57
  9. Marcia Irene Canto · 4 shared papers, 2018–2023 · strength 0.52
  10. Anne Marie Lennon · 4 shared papers, 2021–2023 · strength 0.49
  11. Richard Andrew Burkhart · 5 shared papers, 2020–2022 · strength 0.48
  12. Christopher Lee Wolfgang · 7 shared papers, 2016–2022 · strength 0.46
  13. Robert A. Anders · 3 shared papers, 2021–2026 · strength 0.41
  14. Jun Yu · 6 shared papers, 2012–2022 · strength 0.38
  15. Lei Zheng · 2 shared papers, 2022–2025 · strength 0.38
  16. Nancy R. Porter · 3 shared papers, 2021–2022 · strength 0.37
  17. Elliot K. Fishman · 3 shared papers, 2021–2023 · strength 0.35
  18. Michael Jon Pishvaian · 2 shared papers, 2022–2025 · strength 0.34
  19. George Zogopoulos · 5 shared papers, 2016–2021 · strength 0.33
  20. Sapna Syngal · 6 shared papers, 2012–2021 · strength 0.33
  21. Gloria M. Petersen · 6 shared papers, 2012–2021 · strength 0.33
  22. Matthew John Weiss · 5 shared papers, 2017–2021 · strength 0.33
  23. Amol Kumar Narang · 3 shared papers, 2021–2022 · strength 0.32
  24. Raymond M. Paranal · 1 shared paper, 2024 · strength 0.31
  25. Randall E. Brand · 5 shared papers, 2016–2020 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.